<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-142674" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Thyroid Eye Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shah</surname>
            <given-names>Shalin S.</given-names>
          </name>
          <aff>S N Eye Hospital, Vadodara</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Bhupendra C.</given-names>
          </name>
          <aff>University of Utah</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shalin Shah declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bhupendra Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-142674.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Thyroid eye disease (TED) is a complex inflammatory disorder of the orbit. It involves the orbital fibroblasts, adipocytes, extra-ocular muscles, optic nerve, and the orbital vasculature. The systemic thyroid status can unpredictably affect the course of TED. It is challenging to diagnose TED in euthyroid cases. The clinical presentation ranges from a unilateral dry-eye disease to bilateral sight-threatening complications. The management and rehabilitation strategies are constantly updated. Newer modalities of investigations and treatment are added every day in our armamentarium. This activity reviews the evaluation and management of TED. It also highlights the role of the interprofessional team in effectively managing and rehabilitating the TED patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the pathogenesis of thyroid eye disease.</p></list-item><list-item><p>Describe and review the clinical presentations of thyroid eye disease patients.</p></list-item><list-item><p>Summarize the classification and staging modalities for thyroid eye disease and its applications for long-term follow-up.</p></list-item><list-item><p>Explain the management strategies for visual and cosmetic rehabilitation of thyroid eye disease patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=142674&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=142674">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-142674.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Thyroid eye disease (TED) is a chronic immune-mediated inflammation of the orbit.&#x000a0;It is the most common cause of unilateral and bilateral proptosis in adults.<xref ref-type="bibr" rid="article-142674.r1">[1]</xref>&#x000a0;About 25 to 50% of Grave disease (GD) cases present with thyroid eye disease.<xref ref-type="bibr" rid="article-142674.r2">[2]</xref></p>
        <p>Avicenna and Al-Jurjani first described goiter-associated&#x000a0;ophthalmopathy in AD 1000. Robert Graves, an Irish physician, described four young women with thyrotoxicosis, palpitations, thyroid gland enlargement, and exophthalmos. Graves ophthalmopathy (or TED) is an orbital inflammation or infiltration involving the soft tissues,&#x000a0;proptosis, and ophthalmoplegia.<xref ref-type="bibr" rid="article-142674.r3">[3]</xref>&#x000a0;The definition and understanding of TED have evolved over the years.</p>
      </sec>
      <sec id="article-142674.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of thyroid eye disease is not well understood. TED involves a complex immune-mediated cycle involving the orbital fibroblasts, adipocytes, and lymphocytes.</p>
        <p>Orbital adipose tissue is a unique fat depot. Robust orbital inflammation produces high levels of pro-inflammatory cytokines interleukin IL-1 and prostaglandins.<xref ref-type="bibr" rid="article-142674.r4">[4]</xref>&#x000a0;</p>
        <p>Orbital fibroblasts are the target cells in the pathogenesis of TED. They have increased expression of TSH receptors and can differentiate into mature adipocytes.<xref ref-type="bibr" rid="article-142674.r5">[5]</xref>&#x000a0;A subpopulation of fibroblasts over-expresses the Thy-1 (CD 90) marker.<xref ref-type="bibr" rid="article-142674.r6">[6]</xref>&#x000a0;Transforming growth factor-beta (TGF-B) stimulates the Thy-1 + fibroblasts to differentiate into myofibroblasts. The Thy-1 &#x02013; fibroblasts differentiate into adipocytes on exposure to TGF- B.<xref ref-type="bibr" rid="article-142674.r7">[7]</xref></p>
        <p>TSH receptor (TSH-R) is the primary target of the autoimmune cascade within the orbit.<xref ref-type="bibr" rid="article-142674.r8">[8]</xref>&#x000a0;The serum levels of&#x000a0;anti-thyrotropin receptor antibodies (TRAb) correlate positively with the severity of TED.<xref ref-type="bibr" rid="article-142674.r9">[9]</xref></p>
        <p>Another possible target molecule is the peroxisome-proliferator-activated receptor-gamma present on Thy-1 - fibroblasts.<xref ref-type="bibr" rid="article-142674.r10">[10]</xref>&#x000a0;It is the transcriptional regulator for adipogenesis.<xref ref-type="bibr" rid="article-142674.r11">[11]</xref></p>
        <p>The type 1 insulin-like growth factor receptor (IGF-1R) is another important autoantigen present on Thy-1 + fibroblasts.<xref ref-type="bibr" rid="article-142674.r12">[12]</xref>&#x000a0;Its stimulation enhances the synthesis of IL-16 and RANTES complex. These lead to the recruitment of inflammatory CD4+T-cells in the orbital inflammatory cascade.<xref ref-type="bibr" rid="article-142674.r12">[12]</xref></p>
        <p>In summary, the inflammatory cascade is a positive feedback cycle. Thy-1 &#x02013; fibroblasts activated by TRAb differentiate into adipocytes, secrete IL-6, and recruit B-cells and plasma cells. Thy-1 + fibroblasts, on activation by IGF-1R, secrete IL-16 and RANTES to recruit T-cells. T-cells exhibit CD40-CD154 bridges and are responsible for stimulating IL-1 secretion from fibroblasts.<xref ref-type="bibr" rid="article-142674.r11">[11]</xref>&#x000a0;</p>
        <p>T-cells also produce interferon-gamma and tumor necrosis factor-alpha (TNF-a) to stimulate myofibroblast activity and hyaluronate production. Under the stimulation of IL-6, B-cells produce more auto-antibodies TRAb within the orbit. With prolonged inflammation, the Thy-1 + cell cluster causes fibrosis of EOM - muscle-predominant orbitopathy. TED cases with Thy-1 + cell clusters show enlargement of the orbital adipose tissues - fat-predominant orbitopathy.&#x000a0;Individuals younger than 40 years have a higher Thy-1 &#x02013; response and show orbital fat expansion. TED cases over 70 years of age are more prone to Thy-1 + response and show fusiform muscle enlargement.<xref ref-type="bibr" rid="article-142674.r13">[13]</xref></p>
      </sec>
      <sec id="article-142674.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of thyroid eye disease is approximately 50% among GD patients in the Caucasian population. The annual incidence is 16.0&#x000a0;in 100,000&#x000a0;for females and 2.9&#x000a0;in 100,000 for males in the US population.<xref ref-type="bibr" rid="article-142674.r2">[2]</xref></p>
        <p>
<bold>Risk Factors</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Ethnicity: The African-American population&#x000a0;exhibits the maximal risk, followed by the&#x000a0;White race and Asian populations.<xref ref-type="bibr" rid="article-142674.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Age: TED shows a bimodal peak incidence. It occurs in age groups of 40&#x000a0;to 44 years and 60&#x000a0;to 64 years in females, and ages of 45&#x000a0;to 49 years and 65&#x000a0;to 69 years in males.<xref ref-type="bibr" rid="article-142674.r2">[2]</xref>&#x000a0;It is more severe in older patients with higher chances of restrictive myopathy and dysthyroid optic neuropathy (DON).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gender: There is a female preponderance due to a higher risk of autoimmune diseases. Males cases have more severe ocular involvement and worse outcomes.<xref ref-type="bibr" rid="article-142674.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Genetics: CTLA-4, HLA-DRB-1, and TNF-a genes - are most often associated with TED.<xref ref-type="bibr" rid="article-142674.r16">[16]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Systemic associations: Autoimmune disorders like pernicious anemia, systemic lupus erythematosus, Addison&#x02019;s disease, vitiligo, coeliac disease, and rheumatoid arthritis - a higher risk of TED.<xref ref-type="bibr" rid="article-142674.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Environmental factors: Smoking is strongly associated with the TED incidence.<xref ref-type="bibr" rid="article-142674.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Dysthyroid status: At the time of diagnosis, 90% of TED cases are hyperthyroid, 6% euthyroid, 3% have Hashimoto thyroiditis, and 1% are hypothyroid<xref ref-type="bibr" rid="article-142674.r2">[2]</xref>.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Radioactive iodine therapy (RAIT): causes exacerbation in 24% of TED cases.<xref ref-type="bibr" rid="article-142674.r19">[19]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Stress: Psychological stress&#x000a0;can aggravate TED by rebound immune hyperactivity following prolonged corticosteroid-induced immune suppression.<xref ref-type="bibr" rid="article-142674.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Pregnancy: New onset or worsening of TED occurs in 30% of GD cases in the post-partum period.<xref ref-type="bibr" rid="article-142674.r21">[21]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Others: Trauma can be a stimulus for activating an autoimmune cascade in the orbit. High serum cholesterol may also be a risk factor for TED.<xref ref-type="bibr" rid="article-142674.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-142674.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>TED has a self-limiting course owing to the absence of orbital lymphoid tissue.&#x000a0;</p>
        <p>Rundle explained the natural history of TED.</p>
        <list list-type="order">
          <list-item>
            <p>Initial phase: A steep rise in disease severity, lasting six months &#x02013; to 5 years (avg. two years)</p>
          </list-item>
          <list-item>
            <p>Inflammatory phase: Active TED duration</p>
          </list-item>
          <list-item>
            <p>Stable, inactive phase: TED stabilizes and regresses subsequently beyond 18 months of activity<xref ref-type="bibr" rid="article-142674.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>The disease never returns to baseline. Residual fibrotic changes persist in the orbit.&#x000a0;Aggressive immunosuppressive management during the initial active phase can limit the destructive and fibrotic consequences of the immune cascade. The inactive phase has little response to medical management and warrants surgical intervention.</p>
        <p>The &#x0201c;Cone model&#x0201d; explains the disease progression by an expansion of the muscle cone against a rigid bony orbit into 3 phases:</p>
        <list list-type="order">
          <list-item>
            <p>Circumferential cone expansion &#x02013; displaces the extraconal fat outwards</p>
          </list-item>
          <list-item>
            <p>Axial elongation of cone &#x02013; causes proptosis and muscle strain</p>
          </list-item>
          <list-item>
            <p>Cone hypertension and muscle stiffness &#x02013; impede the orbital venous drainage<xref ref-type="bibr" rid="article-142674.r23">[23]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-142674.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Ocular discomfort - is the most common presentation in thyroid eye disease patients.<xref ref-type="bibr" rid="article-142674.r24">[24]</xref>&#x000a0;Other common complaints are dryness, excessive watering, redness, photophobia, and pain behind the eyes. Visual disturbances like blurring and double vision need prompt intervention. The onset of TED can precede the diagnosis of GD in 19.9% of cases.<xref ref-type="bibr" rid="article-142674.r25">[25]</xref>&#x000a0;Asymmetrical bilateral TED is a common presentation.</p>
        <p>Eyelid retraction is the most common clinical sign of TED, presenting up to 74% of TED cases.</p>
        <p>
<bold>Eyelid Changes</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Lateral flare &#x02013; the altered contour of the upper eyelid is a pathognomonic sign.<xref ref-type="bibr" rid="article-142674.r26">[26]</xref>&#x000a0;It occurs due to scarring between the lacrimal gland fascia and the levator aponeurosis.</p>
          </list-item>
          <list-item>
            <p>Lid lag &#x02013; on a vertical downward pursuit,&#x000a0;the excursion of the upper eyelid lags behind the globe.</p>
          </list-item>
          <list-item>
            <p>Lagophthalmos &#x02013; incomplete eyelid closure&#x000a0;is a classical sign of TED&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lower lid retraction is seen in up to 49% of TED cases<xref ref-type="bibr" rid="article-142674.r27">[27]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Upper lid retraction is seen in around 90&#x000a0;to 98% of TED patients. The mechanisms proposed are as follows:</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Enlargement and fibrosis of levator muscle - the most common muscle targeted by the immune cascade&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Scarring between levator aponeurosis and surrounding soft tissues</p>
          </list-item>
          <list-item>
            <p>Overaction of levator muscle to counteract the ipsilateral tight inferior rectus muscle</p>
          </list-item>
          <list-item>
            <p>Increased sympathetic stimulation of Muller&#x02019;s muscle<xref ref-type="bibr" rid="article-142674.r9">[9]</xref></p>
          </list-item>
        </list>
        <p><bold>Ocular Surface Changes (Active TED Phase)</bold>&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Eyelid-tear film-cornea - the interface is destabilized following inflammatory damage to the conjunctival mucous glands.<xref ref-type="bibr" rid="article-142674.r26">[26]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lacrimal gland inflammation - alters the protein profile of the tear film and reduces the tear secretion rate.</p>
          </list-item>
          <list-item>
            <p>Persistent lagophthalmos disturbs the ocular surface, elevates the tear production rate, and elevates the tear osmolarity.<xref ref-type="bibr" rid="article-142674.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Dry eye symptoms and watering&#x000a0;occurs&#x000a0;in 13 to 20% of patients.</p>
          </list-item>
          <list-item>
            <p>Superior limbic keratoconjunctivitis&#x000a0;is seen in&#x000a0;0.9% of patients.</p>
          </list-item>
          <list-item>
            <p>Persistent dry eye with exposure-keratopathy - 1 to 8% of cases<xref ref-type="bibr" rid="article-142674.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Corneal ulceration, perforation, endophthalmitis - in very severe cases<xref ref-type="bibr" rid="article-142674.r29">[29]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Orbital Changes</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Hypertrophy of the orbital fat and EOM within the bony orbit - raises the intraorbital pressure<xref ref-type="bibr" rid="article-142674.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Forward protrusion of the eyeball - proptosis</p>
          </list-item>
          <list-item>
            <p>Constriction of the superior ophthalmic vein (SOV) by enlarged EOM - venous stasis in TED<xref ref-type="bibr" rid="article-142674.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Venous congestion - redness and swelling of the eyelids, chemosis, caruncular edema<xref ref-type="bibr" rid="article-142674.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Elevation of the episcleral venous pressure - raised intraocular pressure (IOP), open-angle glaucoma<xref ref-type="bibr" rid="article-142674.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Venous and lymphatic stasis in the orbit - prolongs the half-life of inflammatory cytokines, causing a vicious cycle of inflammation<xref ref-type="bibr" rid="article-142674.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Spontaneous fracture of the medial or inferior wall of the orbit - a true, bony &#x02018;auto-decompression&#x02019;<xref ref-type="bibr" rid="article-142674.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>
<bold>EOM Changes</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Inflammation of EOM - during active TED</p>
          </list-item>
          <list-item>
            <p>Infiltration of EOM - accumulation of hyaluronate and late-onset fibrosis<xref ref-type="bibr" rid="article-142674.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Most&#x000a0;commonly involved muscle - inferior rectus (IR), followed by the medial rectus (MR), superior rectus (SR), lateral rectus (LR), and oblique muscles<xref ref-type="bibr" rid="article-142674.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Restrictive strabismus and loss of binocular single vision</p>
          </list-item>
          <list-item>
            <p>Diplopia at presentation - in 6&#x000a0;to 18% of cases<xref ref-type="bibr" rid="article-142674.r2">[2]</xref>. Diplopia in the primary and inferior gaze is the most debilitating complication.</p>
          </list-item>
          <list-item>
            <p>Fluctuation of diplopia with worsening in the morning - during active disease<xref ref-type="bibr" rid="article-142674.r32">[32]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Optic Nerve Changes</bold>
</p>
        <p>Dysthyroid Optic Neuropathy (DON) is a potentially reversible optic nerve dysfunction in 4-10% of TED patients<xref ref-type="bibr" rid="article-142674.r2">[2]</xref>. Early symptoms include diminished vision, altered color vision, diminished contrast sensitivity, and constriction of visual fields (VF). The possible mechanisms are:</p>
        <list list-type="order">
          <list-item>
            <p>Compressive optic neuropathy - most common cause, compression by the enlarged EOM at the orbital apex<xref ref-type="bibr" rid="article-142674.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Optic nerve stretching - in cases of severe fat hypertrophy with proptosis<xref ref-type="bibr" rid="article-142674.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Ischemic optic neuropathy - due to increased resistance to the orbital arterial blood flow, leading to diminished perfusion<xref ref-type="bibr" rid="article-142674.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Enlargement of the superior ophthalmic vein - raises the retro-bulbar pressure and impairs tissue oxygenation.<xref ref-type="bibr" rid="article-142674.r34">[34]</xref></p>
          </list-item>
        </list>
        <table-wrap id="article-142674.table0" position="float" orientation="portrait">
          <table border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 7.40002px;">
                <td style="height: 7.40002px;" rowspan="1" colspan="1">
<bold>Lid Signs</bold>
</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">1. <bold>Dalrymple sign</bold>: Upper eyelid retraction</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">2. <bold>Von Graefe sign</bold>: Lid lag - the upper eyelid lags behind the globe in downgaze</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">3. <bold>Vigoroux sign</bold>: Eyelid fullness/swelling</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">4. <bold>Grove sign</bold>: Resistance on attempting to pull down the retracted upper lid</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">5. <bold>Rosenbach sign</bold>: Fine tremors on attempted closure of the eyelids</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">6. <bold>Gifford sign</bold>: Difficulty in upper eyelid eversion</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">7. <bold>Enroth sign</bold>:&#x000a0; Lower eyelid edema</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">8. <bold>Boston sign</bold>: Jerky irregular movements of the upper eyelid on attempted downgaze</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">9. <bold>Kocher sign</bold>: Increased upper eyelid retraction on visual fixation - staring gaze</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">10. <bold>Abadie sign</bold>:Levator palpebrae superioris (LPS) spasm with upper lid retraction</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">11. <bold>Reesman sign</bold>: Bruit auscultated over the closed eye with a stethoscope</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">12. <bold>Snellen Donder sign</bold>: Bruit heard over the open eye after anesthesia, with a stethoscope</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">13. <bold>Mean sign</bold>: An increase in the superior scleral show on attempted upgaze</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">
<bold>Facial Signs</bold>
</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">1. <bold>Stellwag sign</bold>: Incomplete and infrequent blinking</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">2. <bold>Joffroy sign</bold>: Absent forehead creases on upgaze</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">3. <bold>Jellinek sign</bold>: Hyperpigmentation of the upper eyelid folds</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">4. <bold>Hertoge sign</bold>: Loss of cilia on the lateral third eyebrow</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">5. <bold>Sainton sign</bold>: Delayed wrinkling of the forehead on up gaze</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">6. <bold>Pochin sign</bold>: Increased blinking amplitude</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">
<bold>EOM Signs</bold>
</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">1. <bold>M&#x000f6;bius Sign</bold>: Convergence insufficiency</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">2. <bold>Sattler sign</bold>: Increased IOP on attempted upgaze</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">3. <bold>Ballet sign</bold>: EOM restriction</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px;" rowspan="1" colspan="1">4.<bold> Jendrassik sign</bold>: Abduction limitation of the eyeballs</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">5.<bold> Suker sign</bold>: Poor fixation on attempted abduction</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">6. <bold>Wilder sign</bold>: Jerky eye movements on attempted adduction from full abduction</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>Pupillary Signs</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">1. <bold>Cowen sign:</bold> Jerky constriction to light</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">2. <bold>Loewi sign:</bold> Mydriasis with topical adrenaline 1:1000 concentration</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">3. <bold>Knies sign:</bold> Unequal dilation in dim light</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>Other Signs</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">1. <bold>Goldzeiher sign</bold>: Deep injection of the bulbar conjunctiva</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">2.<bold> Payne-Trousseau sign</bold>: Globe luxation</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-142674.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Thyroid eye disease&#x000a0;cases are clinically evaluated as the activity and severity of the disease. The activity represents the grade of active inflammation and defines the progression of the disease. The&#x000a0;severity reflects the spectrum of functional and cosmetic deficits.&#x000a0;Numerous classification systems have come up over the last century to assess and grade the clinical manifestations of TED.&#x000a0;</p>
        <p>The most well-known system &#x02013; is the NO SPECS classification.<xref ref-type="bibr" rid="article-142674.r35">[35]</xref>&#x000a0;The American Thyroid Association introduced this classification in 1969. It was updated in 1977 to the modified NO SPECS classification.<xref ref-type="bibr" rid="article-142674.r36">[36]</xref></p>
        <table-wrap id="article-142674.table1" position="float" orientation="portrait">
          <table style="width: 670px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>Class</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">
<bold>Grade</bold>
</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>&#x000a0;0</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">No physical signs or symptoms</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>I</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">
<bold>Only signs</bold>
</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>II</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">
<bold>Soft tissue involvement</bold>
</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>&#x000a0;II-0</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Absent</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>&#x000a0;II-1</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Minimal</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>&#x000a0;II-2</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Moderate</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>&#x000a0;II-3</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Marked</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>III&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">
<bold>Proptosis (&#x0003e; 2 mm of the normal upper limits)</bold>
</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>III-1&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">3-4 mm</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>III-2&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">5-7 mm</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>III-3&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">&#x0003e;&#x000a0;8 mm&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>IV&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">
<bold>Extraocular muscle involvement (usually with diplopia)</bold>
</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>IV-0&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Absent</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>IV-1&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Limitation of motion at the extremes of gaze</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>IV-2&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Evident restriction of movements</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>IV-3&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Fixed globe/globes</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>V&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">
<bold>Corneal involvement (due to lagophthalmos)</bold>
</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>V-0&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Absent</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>V-1&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Stippling of cornea</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>V-2&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Ulceration</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>V-3&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Clouding, necrosis, and perforation</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>VI</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">
<bold>Sight loss (optic nerve involvement)</bold>
</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>VI-0&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Absent</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>&#x000a0;VI-1</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Disc pallor or VF defect, vision 20/20&#x02013;20/60</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>VI-2&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Disc pallor or VF defect, vision 20/70&#x02013;20/200</td>
              </tr>
              <tr>
                <td style="width: 41.25px;" rowspan="1" colspan="1">
<bold>VI-3&#x000a0;</bold>
</td>
                <td style="width: 560.75px;" rowspan="1" colspan="1">Blindness, vision less than 20/200</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>In 1981, Von Dyek proposed the RELIEF variation of the NO SPECS classification.<xref ref-type="bibr" rid="article-142674.r37">[37]</xref></p>
        <p>The NO SPECS system only grades the clinical severity of TED. It doesn't include the activity of the disease. This classification system dictates the treatment strategies without considering the status of active inflammation. This system is now obsolete.</p>
        <table-wrap id="article-142674.table2" position="float" orientation="portrait">
          <table style="width: 401.8px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 366.8px;" rowspan="1" colspan="1">R - Resistance to retropulsion</td>
              </tr>
              <tr>
                <td style="width: 366.8px;" rowspan="1" colspan="1">E - Edema of the conjunctiva and caruncle</td>
              </tr>
              <tr>
                <td style="width: 366.8px;" rowspan="1" colspan="1">L - Lacrimal gland enlargement</td>
              </tr>
              <tr>
                <td style="width: 366.8px;" rowspan="1" colspan="1">I - Injection over Horizontal rectus muscle insertions</td>
              </tr>
              <tr>
                <td style="width: 366.8px;" rowspan="1" colspan="1">E - Edema of the eyelids</td>
              </tr>
              <tr>
                <td style="width: 366.8px;" rowspan="1" colspan="1">F - Fullness of the eyelids</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>A new system &#x02013; <bold>Clinical Activity Score (CAS),</bold> was proposed in 1989, considering the classic signs of inflammation &#x02013; pain, swelling, redness, and impaired function.&#x000a0;The European Group on Graves Orbitopathy (EUGOGO) later amended the CAS system.&#x000a0;As per the amended CAS, active TED has a score of &#x0003e; 3/7 at the first visit or &#x0003e; 4/10 at subsequent visits.<xref ref-type="bibr" rid="article-142674.r38">[38]</xref></p>
        <table-wrap id="article-142674.table3" position="float" orientation="portrait">
          <table style="width: 769.8px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 734.8px; height: 13px;" rowspan="1" colspan="1">
<bold>For Initial CAS, Score Items 1-7 only</bold>
</td>
              </tr>
              <tr style="height: 84px;">
                <td style="width: 734.8px; height: 84px;" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Spontaneous orbital pain</p></list-item><list-item><p>Gaze-evoked orbital pain</p></list-item><list-item><p>Lid edema</p></list-item><list-item><p>Lid erythema</p></list-item><list-item><p>Conjunctival congestion (involving &#x0003e; 1 quadrant)</p></list-item><list-item><p>Chemosis</p></list-item><list-item><p>Caruncular edema</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 734.8px; height: 13px;" rowspan="1" colspan="1">
<bold>At the Follow-up Visit (1-3 months), a Score Out of 10 (including items 8-10)</bold>
</td>
              </tr>
              <tr style="height: 13.8572px;">
                <td style="width: 734.8px; height: 13.8572px;" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Increase of &#x0003e; 2 mm in proptosis</p></list-item><list-item><p>Diminished uniocular excursion in any direction of &#x0003e; 8 degrees</p></list-item><list-item><p>Decrease of visual acuity equivalent to &#x0003e; 1 Snellen line</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The <bold>EUGOGO</bold>&#x000a0;proposed a severity assessment protocol to grade the severity of TED into mild, moderate-to-severe, and sight-threatening categories&#x000a0;as&#x000a0;summarised below:</p>
        <p>
<bold>Soft Tissue Assessment (Pain not included)</bold>
</p>
        <p><bold>Eyelid Swelling</bold>&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Absent</p>
          </list-item>
          <list-item>
            <p>Mild: none of the features defining moderate or severe categories</p>
          </list-item>
          <list-item>
            <p>Moderate: definite swelling, no lower eyelid festoons OR angulation of the upper eyelid skin fold in downgaze</p>
          </list-item>
          <list-item>
            <p>Severe: lower eyelid festoons OR upper lid fold becomes rounded at 45 degrees downgaze</p>
          </list-item>
        </list>
        <p>
<bold>Eyelid Erythema</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Absent</p>
          </list-item>
          <list-item>
            <p>Present</p>
          </list-item>
        </list>
        <p>
<bold>Conjunctival Redness</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Absent</p>
          </list-item>
          <list-item>
            <p>Mild: equivocal or minimal&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Moderate: &#x0003c;50% of definite conjunctival involvement</p>
          </list-item>
          <list-item>
            <p>Severe: &#x0003e;50% of definite conjunctival involvement</p>
          </list-item>
        </list>
        <p>
<bold>Conjunctival Edema</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Absent</p>
          </list-item>
          <list-item>
            <p>Present: separation of conjunctiva from sclera present in &#x0003e;1/3 of the total height of the palpebral aperture OR the conjunctiva prolapses anterior to the grey line of the eyelid</p>
          </list-item>
        </list>
        <p>
<bold>Inflammation of Caruncle or Plica Semilunaris</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Absent</p>
          </list-item>
          <list-item>
            <p>Present: plica prolapses through the closed eyelids OR inflammation of caruncle or plica&#x000a0;</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Lid Margin Assessment (at the mid-pupillary line)</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Palpebral aperture (mm)</p>
          </list-item>
          <list-item>
            <p>Upper/lower lid retraction (mm)</p>
          </list-item>
          <list-item>
            <p>Levator function (mm)</p>
          </list-item>
          <list-item>
            <p>Lagophthalmos -&#x000a0;Absent or present</p>
          </list-item>
          <list-item>
            <p>Bell's phenomenon -&#x000a0;Absent or present</p>
          </list-item>
        </list>
        <p><bold>Proptosis Assessment</bold> - using Hertel exophthalmometery&#x000a0;to record the intercanthal distance</p>
        <p>
<bold>Ocular Motility Assessment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The prism cover test</p>
          </list-item>
          <list-item>
            <p>Monocular ductions</p>
          </list-item>
          <list-item>
            <p>Head posture</p>
          </list-item>
          <list-item>
            <p>Torsion</p>
          </list-item>
          <list-item>
            <p>Binocular single vision</p>
          </list-item>
        </list>
        <p>
<bold>Corneal Integrity Assessment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Normal</p>
          </list-item>
          <list-item>
            <p>Punctate keratopathy</p>
          </list-item>
          <list-item>
            <p>Ulcer</p>
          </list-item>
          <list-item>
            <p>Perforation</p>
          </list-item>
        </list>
        <p>
<bold>Optic Nerve Assessment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Visual acuity (LogMAR or Snellen)</p>
          </list-item>
          <list-item>
            <p>Afferent pupil defect (present/absent)</p>
          </list-item>
          <list-item>
            <p>Colour vision</p>
          </list-item>
          <list-item>
            <p>VF analysis</p>
          </list-item>
          <list-item>
            <p>Optic disc assessment - normal/atrophy/edema</p>
          </list-item>
        </list>
        <table-wrap id="article-142674.table4" position="float" orientation="portrait">
          <table style="width: 634px; height: 323px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 98px;">
                <td style="width: 125.312px; height: 98px;" rowspan="1" colspan="1">
<bold>Mild</bold>
</td>
                <td style="width: 420.973px; height: 98px;" rowspan="1" colspan="1">
<p>One or more of the following:&#x000a0;</p>
<list list-type="order"><list-item><p>Minor lid retraction &#x0003c; 2mm</p></list-item><list-item><p>Mild soft-tissue involvement&#x000a0;</p></list-item><list-item><p>Exophthalmos &#x0003c; 3mm above the normal (for the gender and race)&#x000a0;</p></list-item><list-item><p>Transient or no diplopia</p></list-item></list>
</td>
              </tr>
              <tr style="height: 98px;">
                <td style="width: 125.312px; height: 98px;" rowspan="1" colspan="1">
<bold>Moderate-to-Severe</bold>
</td>
                <td style="width: 420.973px; height: 98px;" rowspan="1" colspan="1">
<p>One or more of the following:&#x000a0;</p>
<list list-type="order"><list-item><p>Lid retraction &#x0003e; 2mm</p></list-item><list-item><p>Moderate-to-severe soft-tissue involvement&#x000a0;</p></list-item><list-item><p>Exophthalmos &#x0003e; 3mm above normal (for the gender and race)&#x000a0;</p></list-item><list-item><p>Inconstant or constant diplopia</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13.7144px;">
                <td style="width: 125.312px; height: 13.7144px;" rowspan="1" colspan="1">
<bold>Sight-Threatening</bold>
</td>
                <td style="width: 420.973px; height: 13.7144px;" rowspan="1" colspan="1">Dysthyroid optic neuropathy and/or Corneal breakdown</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>A novel classification &#x02013; the&#x000a0;<bold>VISA </bold>system, was proposed in 2006 with four parameters &#x02013; Vision, Inflammation/congestion, Strabismus/motility restriction, and Appearance/exposure. The International Thyroid Eye Disease Society (ITEDS) 2018 defined separate parameters for the assessment at the first and subsequent visits.</p>
        <p><bold>Inflammation (I) score </bold>&#x0003c; 4/10, is an inactive disease -&#x000a0; manage conservatively. Score &#x0003e; 5/10 with evidence of progression of inflammation - manage aggressively&#x000a0;&#x000a0;</p>
        <p>The clinical assessment and scoring are similar to CAS-EUGOGO recommendations except for the following changes.</p>
        <p><bold>Chemosis</bold>: +1 point if the conjunctiva lies behind the grey line of the lid, +2 if the conjunctiva extends anterior to the grey line</p>
        <p><bold>Lid edema</bold>: +1 if no overhanging of tissues, +2 if upper eyelid skin folds or lower lid festoons are present</p>
        <p><bold>Strabismus/motility restriction</bold>: Ductions - measured to the nearest five degrees in all four gazes, using the corneal reflex method. Any change in the ductions of &#x0003e; 12 degrees in any direction suggests progression.</p>
        <p>Clinical assessment protocols given by the VISA and EUGOGO teams are not interchangeable. Hence only a single system is used for a specific patient.&#x000a0;</p>
        <p>All the scoring systems focus on a qualitative assessment. They give an equal weightage to all the symptoms, regardless of their diagnostic significance. This undermines the accurate monitoring of the disease progression. The arbitrarily chosen cut-off points (3/7 or 4/10 in CAS scoring) may not accurately reflect the extent of the disease.</p>
        <p>
<bold>Orbital Imaging</bold>
<bold>&#x000a0;&#x000a0;</bold>
</p>
        <p>Orbital imaging provides valuable insights into the diagnosis and management of TED.</p>
        <p>
<bold>Computed Tomography (CT) Scan</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Characteristic fusiform enlargement of EOM - enlarged muscle belly with relative sparing of tendons. Long-standing cases show significant EOM changes - the "coca-cola sign." Orbital imaging in unilateral TED cases confirms the presence of asymmetric bilateral EOM changes.<xref ref-type="bibr" rid="article-142674.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Barrett's index &#x02013; for quantitative measurement of EOM thickness and apical crowding.<xref ref-type="bibr" rid="article-142674.r40">[40]</xref>&#x000a0;The vertical index is&#x000a0;the division of the sum of vertical muscle diameters by the height of the orbit. The horizontal index is calculated similarly. The greater of the two ratios is Barret's index. A Barrett's muscle index of &#x0003e;67% is predictive of optic neuropathy.<xref ref-type="bibr" rid="article-142674.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p>Imaging in DON - soft tissue signs like apical crowding, enlarged superior ophthalmic vein,&#x000a0;enlarged EOM (especially MR), Barrett's muscle index &#x0003e;67%, orbital fat prolapse across the superior orbital fissure, perineural fat effacement,&#x000a0;and enlarged lacrimal gland.&#x000a0;The bony orbit signs - the increased angle of the orbital apex&#x000a0;and an increased angle of the medial wall. Coronal CT scan of orbital apex shows a narrow clear ring of low density around the optic nerve due to bulging adipose tissue. Stretch neuropathy is diagnosed by "taut nerve" in severe proptosis cases.</p>
          </list-item>
          <list-item>
            <p>Classification of orbitopathy&#x000a0;&#x02013; type 1: lipogenic variant, type 2: myogenic variant, and type 3: mixed variant. Accurate coronal images aid the detection of soft tissue remodeling &#x02013; EOM and fat enlargement.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>CT exophthalmometry - is the gold standard. It is accurate, reproducible, and unaffected by periorbital tissue edema. The interzygomatic line (IZL) connects the ventral zygomatic borders bilaterally in axial view.&#x000a0;The various techniques using IZL are:</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The perpendicular distance between the anterior surface of the cornea and IZL corresponds to the Hertel exophthalmometry value.<xref ref-type="bibr" rid="article-142674.r42">[42]</xref></p>
          </list-item>
          <list-item>
            <p>The distance between IZL and the posterior sclera (normal value = 9.9 + 1.9 mm).<xref ref-type="bibr" rid="article-142674.r43">[43]</xref></p>
          </list-item>
          <list-item>
            <p>The observation of less than 1/3rd of the globe lying behind IZL.<xref ref-type="bibr" rid="article-142674.r42">[42]</xref></p>
          </list-item>
        </list>
        <p>This technique&#x000a0;is not feasible in patients who underwent lateral wall decompression surgery. A novel method uses the posterior clinoid (PC) process as a landmark and measures the distance between the PC and the anterior corneal surface<xref ref-type="bibr" rid="article-142674.r44">[44]</xref></p>
        <p>&#x000a0;<bold>Magnetic Resonance Imaging (MRI) Scan</bold></p>
        <p>Better for disease activity assessment.&#x000a0;The MR parameters - T2 signal intensity ratio, T1 signal intensity ratio following gadolinium administration, and apparent diffusion coefficient correlate positively with CAS. In T1 weighted images, EOM appears isointense to facial muscles in inactive TED, with enhancement on Gadolinium contrast.<xref ref-type="bibr" rid="article-142674.r45">[45]</xref>&#x000a0;In T2 weighted images, EOM appears hyperintense during active TED and hypointense during inactive TED.<xref ref-type="bibr" rid="article-142674.r39">[39]</xref></p>
        <p>
<bold>Orbital Color Doppler Imaging (CDI)</bold>
</p>
        <p>Evaluates the hemodynamic changes in orbit, secondary to increase in orbital volume. The primary vessels imaged are the ophthalmic artery, central retinal artery, and superior ophthalmic vein. The peak systolic velocity, end-diastolic velocity, and resistivity index are important indicators of ocular perfusion.<xref ref-type="bibr" rid="article-142674.r46">[46]</xref></p>
      </sec>
      <sec id="article-142674.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Prevention</bold>
</p>
        <p>Clinical assessment and accurate grading of thyroid eye disease are essential for appropriate management.&#x000a0;</p>
        <p><bold>Primary Prevention </bold>&#x02013; Smoking cessation<xref ref-type="bibr" rid="article-142674.r47">[47]</xref></p>
        <p><bold>Secondary Prevention</bold> &#x02013; Early detection of any dysthyroid state and prompt management to prevent disease progression.&#x000a0;</p>
        <p><bold>Tertiary Prevention</bold> &#x02013;&#x000a0; Artificial tears prevent the risk of exposure-keratopathy.<xref ref-type="bibr" rid="article-142674.r48">[48]</xref>&#x000a0;Cosmetic and visual rehabilitation is essential.&#x000a0;</p>
        <p>
<bold>Medical Management</bold>
</p>
        <p>Prompt restoration of euthyroid status is essential.<xref ref-type="bibr" rid="article-142674.r49">[49]</xref></p>
        <p>
<bold>Mild TED</bold>
</p>
        <p>Patients with corneal exposure and ocular surface symptoms require extensive lubrication with artificial tears, gels, and ointments. Over-night lid tapping, occlusive eye-pads, cold compresses, or sleeping with head-end elevation &#x02013; are of questionable benefit.</p>
        <p>Selenium supplements improve the quality of life, reduce inflammation, and retards TED progression.<xref ref-type="bibr" rid="article-142674.r50">[50]</xref></p>
        <p>Lid retraction &#x0003c; 2 mm is managed by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Transconjunctival injection - 5 unit botulinum toxin type A&#x000a0;in LPS&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Transconjunctival injection - 10 mg of triamcinolone&#x000a0;in LPS</p>
          </list-item>
        </list>
        <p>Both techniques show excellent results with the resolution of lid retraction.</p>
        <p>&#x000a0;<bold>Moderate-to-Severe TED</bold></p>
        <p>
<bold>Active Cases&#x000a0;</bold>
</p>
        <p>Early immunosuppression is essential.</p>
        <p><bold>Corticosteroids:</bold>&#x000a0;the first-line agent&#x000a0;</p>
        <p>EUGOGO management protocol is low-dose pulse therapy with intravenous methylprednisolone (IVMP). 500 mg IVMP is administered weekly for the initial six weeks.&#x000a0;Over the next six weeks, the dose is tapered to 250 mg weekly.<xref ref-type="bibr" rid="article-142674.r51">[51]</xref>&#x000a0;Severe active cases require prolonged oral corticosteroids for six months.&#x000a0;Withdrawl of steroids can show disease flare-ups. Adjuvant orbital radiotherapy helps prevent flare-ups.<xref ref-type="bibr" rid="article-142674.r52">[52]</xref></p>
        <p><bold>Immunomodulators: </bold>the&#x000a0;second-line agents</p>
        <p>Indications - steroid intolerance, steroid dependence, disease refractory to steroids, contraindications to steroid use</p>
        <p>Methotrexate - weekly dosing of 7.5&#x000a0;to 10 mg shows a significant improvement in CAS and ocular motility within 12 months of treatment<xref ref-type="bibr" rid="article-142674.r53">[53]</xref></p>
        <p>Azathioprine - combined with low dose orbital radiation or IVMP for moderate-to-severe TED<xref ref-type="bibr" rid="article-142674.r54">[54]</xref></p>
        <p>Mycophenolate mofetil - standalone therapy shows better CAS response with minimal disease reactivation<xref ref-type="bibr" rid="article-142674.r55">[55]</xref></p>
        <p>
<bold>Immunobiologicals</bold>
</p>
        <p>Rituximab - a humanized chimeric monoclonal antibody targeting CD 20 on B-cells, shows 100% response and minimal reactivation in moderate-to-severe TED.<xref ref-type="bibr" rid="article-142674.r56">[56]</xref>&#x000a0;</p>
        <p>Tocilizumab (anti-IL-6 receptor antibody), adalimumab (anti-TNF-a antibody), and infliximab (anti-TNF-a antibody)&#x000a0;also show promising results.</p>
        <p>Teprotumumab, a specific IGF-1R blocker, is a novel molecule. It is administered as eight infusions over 24 weeks. The improvement in CAS, proptosis, diplopia, and quality of life, with a reduction in proptosis, is comparable to surgical orbital decompression.<xref ref-type="bibr" rid="article-142674.r57">[57]</xref></p>
        <p>
<bold>Inactive Cases</bold>
</p>
        <p>For cases with lagophthalmos, dry-eye disease symptoms, and exposure keratopathy, adequate lubrication is advised.</p>
        <p>Appropriate surgical management yields good cosmetic results for residual proptosis, strabismus, lid retraction, and significant lagophthalmos.&#x000a0;</p>
        <p>
<bold>Sight-Threatening Disease</bold>
</p>
        <p>High-dose systemic corticosteroid, 1 g IVMP for three days, is the most effective therapy for DON cases.<xref ref-type="bibr" rid="article-142674.r58">[58]</xref>&#x000a0;Orbital radiotherapy is the second-line management for DON cases, with a reduced need for surgical orbital decompression.&#x000a0;</p>
        <p>
<bold>Surgical Management</bold>
</p>
        <p>Elective surgical options are reserved for inactive thyroid eye disease cases not responding to conservative or maximal medical management. During cosmetic rehabilitation,&#x000a0;orbital decompression surgery is the primary procedure to correct proptosis. After six months, strabismus surgery achieves adequate ocular alignment.&#x000a0;After an additional six months, a definitive lid retraction surgery helps restore the cosmetic and functional status.</p>
        <p>Indications for orbital decompression in stable inactive TED are corneal exposure, DON, disfiguring proptosis, chronic pain/ discomfort, and congestion.<xref ref-type="bibr" rid="article-142674.r59">[59]</xref>&#x000a0;Urgent orbital decompression is reserved for active TED with DON, not responding to high dose IVMP.<xref ref-type="bibr" rid="article-142674.r60">[60]</xref></p>
        <p>The surgical approaches are customized:</p>
        <list list-type="order">
          <list-item>
            <p>Lateral wall decompression - by Kronlein, modified Kronlein, Stallard-Wright, Berke, and lateral eyelid crease incisions. The preferred technique is ab interno bone removal with sparing of the lateral orbital rim.<xref ref-type="bibr" rid="article-142674.r61">[61]</xref>&#x000a0;Complications include intraoperative CSF leak, infra-orbital anesthesia, and new-onset diplopia.<xref ref-type="bibr" rid="article-142674.r62">[62]</xref></p>
          </list-item>
          <list-item>
            <p>Medial wall decompression - using trans-cutaneous, trans-conjunctival, or trans-nasal approaches.&#x000a0;The transnasal endoscopic approach is ideal for medial wall surgeries.<xref ref-type="bibr" rid="article-142674.r63">[63]</xref></p>
          </list-item>
          <list-item>
            <p>Floor decompression -&#x000a0;trans-orbital approach by trans-cutaneous or trans-conjunctival incisions&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Two wall decompressions - combined medial wall and floor removal<xref ref-type="bibr" rid="article-142674.r64">[64]</xref></p>
          </list-item>
          <list-item>
            <p>Combined lateral wall and floor decompression - trans-conjunctival or trans canthal swinging lid crease approach<xref ref-type="bibr" rid="article-142674.r65">[65]</xref></p>
          </list-item>
          <list-item>
            <p>Three walls &#x02013; floor, lateral wall, and medial wall, and sparing of the orbital roof</p>
          </list-item>
          <list-item>
            <p>Four wall decompression &#x02013; floor, medial wall, lateral wall, posterolateral roof<xref ref-type="bibr" rid="article-142674.r66">[66]</xref></p>
          </list-item>
          <list-item>
            <p>Fat decompression - in fat-predominant orbitopathy<xref ref-type="bibr" rid="article-142674.r67">[67]</xref></p>
          </list-item>
          <list-item>
            <p>Balanced decompression &#x02013; medial + lateral wall.<xref ref-type="bibr" rid="article-142674.r68">[68]</xref>&#x000a0;The rate of new-onset strabismus is lower with a balanced decompression.<xref ref-type="bibr" rid="article-142674.r69">[69]</xref></p>
          </list-item>
        </list>
        <p>Surgical orbital decompression corrects the proptosis of&#x000a0;2&#x000a0;to 2.5 mm per wall.<xref ref-type="bibr" rid="article-142674.r70">[70]</xref>&#x000a0;Fat is the fifth wall of the orbit for surgical decompression.<xref ref-type="bibr" rid="article-142674.r68">[68]</xref></p>
      </sec>
      <sec id="article-142674.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Non-specific orbital inflammatory disease (NSOID): Bilateral proptosis with lacrimal gland enlargement. EOM enlargement involves the muscle belly and the tendinous origin. The lacrimal gland enlarges and prolapses out of the lacrimal fossa. It can be associated with systemic autoimmune diseases like polymyositis, dermatomyositis, and IGG4-related diseases. Serology and soft tissue biopsy are diagnostic.<xref ref-type="bibr" rid="article-142674.r71">[71]</xref></p>
        <p>Lymphoma: Bilateral proptosis with lymphadenopathy. Hemogram and blood counts are usually normal. Orbital CT scan shows bilateral diffuse soft tissue enlargement with the erosion of the bony orbit. Histopathology and immunohistochemistry features on the soft tissue biopsy are diagnostic.<xref ref-type="bibr" rid="article-142674.r72">[72]</xref></p>
        <p>Blow-out fracture of the orbit: Altered globe position and limitation of EOM movements. History of trauma is followed by enophthalmos and restriction of elevation. An orbital CT scan shows the bony defect with entrapped soft tissues.<xref ref-type="bibr" rid="article-142674.r73">[73]</xref></p>
        <p>Amyloidosis: Bilateral proptosis with neuropathy. Soft tissue biopsy shows eosinophilic material on histopathology with birefringence on polarised light microscopy.<xref ref-type="bibr" rid="article-142674.r74">[74]</xref></p>
      </sec>
      <sec id="article-142674.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Approximately 80% of thyroid eye disease cases require conservative management with topical lubricant eye drops. 5% of TED cases need systemic corticosteroids or immunomodulation. About&#x000a0;20% of the patients undergo some form of surgical intervention. Long-term follow-up and strict monitoring for disease complications are essential.</p>
      </sec>
      <sec id="article-142674.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Thyroid eye disease cases can present with the following complications:</p>
        <list list-type="order">
          <list-item>
            <p>Dysthyroid optic neuropathy - compressive or ischemic</p>
          </list-item>
          <list-item>
            <p>Optic atrophy</p>
          </list-item>
          <list-item>
            <p>Exposure-keratopathy and keratomalacia</p>
          </list-item>
          <list-item>
            <p>Open-angle glaucoma</p>
          </list-item>
          <list-item>
            <p>Restrictive strabismus and diplopia</p>
          </list-item>
          <list-item>
            <p>Persistent proptosis, lid retraction, cosmetic disfigurement</p>
          </list-item>
          <list-item>
            <p>Orbital venous stasis and venous occlusions<xref ref-type="bibr" rid="article-142674.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-142674.s12" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Cosmetic rehabilitation is essential in TED management. Asymmetrical proptosis is common during inactive disease. A graded surgical orbital decompression helps achieve a cosmetically symmetrical look.</p>
        <p>The surgical plan is customized depending on the amount of proptosis correction, the pattern of strabismus, and the orbital anatomy. The restricted EOM is recessed to achieve orthophoria in the primary gaze. The final correction for the lid retraction is planned at least six months after the strabismus surgery. Blepharotomy, blepahromyotomy, levator recession, and spacer grafts are the common strategies for lid retraction correction.<xref ref-type="bibr" rid="article-142674.r75">[75]</xref></p>
      </sec>
      <sec id="article-142674.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>All patients with thyroid disorders should be routinely screened for early signs of thyroid eye disease. Regular follow-up of asymptomatic GD and mild TED cases can help prompt diagnosis and management of sight-threatening complications. The patients should be explained the early signs of DON - altered color vision, diminished contrast sensitivity, decreased field of vision, and decreased visual acuity.</p>
      </sec>
      <sec id="article-142674.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>A high index of suspicion is essential for patients with the classic symptoms of thyroid eye disease, with no history of thyroid disorders or a euthyroid status at presentation. An endocrine workup and orbital imaging are essential for a definite diagnosis in the absence of classical clinical presentation.&#x000a0;</p>
        <p>The management includes strict maintenance of euthyroid status, cessation of smoking, adequate lubrication, adequate control of the IOP, and monitoring of disease progression as per the CAS / VISA scoring systems at regular follow-ups. Any sign of progression to active disease or sight-threatening disease warrants urgent management.</p>
      </sec>
      <sec id="article-142674.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Thyroid eye disease cases require a multi-specialty effort for early diagnosis and timely management. Physicians and endocrinologists are the primary contacts for thyroid disorder cases. All predisposed patients should undergo regular eye checkups. Long-term sustenance of euthyroid status is the foremost pillar for TED prevention.&#x000a0;</p>
        <p>Appropriate control of smoking and nicotine addiction is necessary with the involvement of psychiatrists, de-addiction clinics, anonymous support groups, counseling, and patient deterrence. The sight-threatening disease and cosmetic disfigurement are also a source of anxiety for the patients. Trained professionals are necessary to deal with psychosocial issues.&#x000a0;</p>
        <p>Ophthalmologists and oculoplastic personnel play an essential role in the long-term follow-up, medical, and surgical management of TED cases. Visual and cosmetic rehabilitation are important end-points of TED management.</p>
      </sec>
      <sec id="article-142674.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=142674&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=142674">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/thyroid-eye-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=142674">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/142674/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=142674">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-142674.s17">
        <title>References</title>
        <ref id="article-142674.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiersinga</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Bartalena</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and prevention of Graves' ophthalmopathy.</article-title>
            <source>Thyroid</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>855</fpage>
            <page-range>855-60</page-range>
            <pub-id pub-id-type="pmid">12487767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartley</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>1994</year>
            <volume>92</volume>
            <fpage>477</fpage>
            <page-range>477-588</page-range>
            <pub-id pub-id-type="pmid">7886878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKenzie</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Humoral factors in the pathogenesis of Graves' disease.</article-title>
            <source>Physiol Rev</source>
            <year>1968</year>
            <month>Jan</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>252</fpage>
            <page-range>252-310</page-range>
            <pub-id pub-id-type="pmid">4865519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moshkelgosha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Deasy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Diaz-Cano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Banga</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation.</article-title>
            <source>Endocrinology</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>154</volume>
            <issue>9</issue>
            <fpage>3008</fpage>
            <page-range>3008-15</page-range>
            <pub-id pub-id-type="pmid">23900776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valyasevi</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Harteneck</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Dutton</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Heufelder</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Jyonouchi</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Bahn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>84</volume>
            <issue>7</issue>
            <fpage>2557</fpage>
            <page-range>2557-62</page-range>
            <pub-id pub-id-type="pmid">10404836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoo</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Coenen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Schiefer</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bahn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy.</article-title>
            <source>Thyroid</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>1291</fpage>
            <page-range>1291-6</page-range>
            <pub-id pub-id-type="pmid">18976167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Koumas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gagnon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sempowski</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Phipps</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Sorisky</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>87</volume>
            <issue>1</issue>
            <fpage>385</fpage>
            <page-range>385-92</page-range>
            <pub-id pub-id-type="pmid">11788681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feliciello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porcellini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ciullo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bonavolont&#x000e0;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Avvedimento</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Fenzi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue.</article-title>
            <source>Lancet</source>
            <year>1993</year>
            <month>Aug</month>
            <day>07</day>
            <volume>342</volume>
            <issue>8867</issue>
            <fpage>337</fpage>
            <page-range>337-8</page-range>
            <pub-id pub-id-type="pmid">8101586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Graves' ophthalmopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Feb</month>
            <day>25</day>
            <volume>362</volume>
            <issue>8</issue>
            <fpage>726</fpage>
            <page-range>726-38</page-range>
            <pub-id pub-id-type="pmid">20181974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mazzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Profilo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mautone</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Casini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rocchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ionni</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Menconi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marin&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study.</article-title>
            <source>Thyroid</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>386</fpage>
            <page-range>386-394</page-range>
            <pub-id pub-id-type="pmid">29336220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>MacDougald</surname>
                <given-names>OA</given-names>
              </name>
            </person-group>
            <article-title>Adipocyte differentiation from the inside out.</article-title>
            <source>Nat Rev Mol Cell Biol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>885</fpage>
            <page-range>885-96</page-range>
            <pub-id pub-id-type="pmid">17139329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pritchard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Horst</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cruikshank</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.</article-title>
            <source>J Immunol</source>
            <year>2003</year>
            <month>Jun</month>
            <day>15</day>
            <volume>170</volume>
            <issue>12</issue>
            <fpage>6348</fpage>
            <page-range>6348-54</page-range>
            <pub-id pub-id-type="pmid">12794168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2003</year>
            <month>May</month>
            <volume>88</volume>
            <issue>5</issue>
            <fpage>1939</fpage>
            <page-range>1939-46</page-range>
            <pub-id pub-id-type="pmid">12727937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stan</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Bahn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for development or deterioration of Graves' ophthalmopathy.</article-title>
            <source>Thyroid</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>777</fpage>
            <page-range>777-83</page-range>
            <pub-id pub-id-type="pmid">20578901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perros</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Crombie</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Kendall-Taylor</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>367</fpage>
            <page-range>367-72</page-range>
            <pub-id pub-id-type="pmid">8319368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalilzadeh</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Noshad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rashidi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amirzargar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Graves' ophthalmopathy: a review of immunogenetics.</article-title>
            <source>Curr Genomics</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>564</fpage>
            <page-range>564-75</page-range>
            <pub-id pub-id-type="pmid">22654556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boelaert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Simmonds</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Holder</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Carr-Smith</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Heward</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Manji</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Allahabadia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gough</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Franklyn</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease.</article-title>
            <source>Am J Med</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>123</volume>
            <issue>2</issue>
            <fpage>183.e1</fpage>
            <page-range>183.e1-9</page-range>
            <pub-id pub-id-type="pmid">20103030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prummel</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Wiersinga</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Smoking a risk factor for hypothyroidism [correction of hyperthyroidism].</article-title>
            <source>J Endocrinol Invest</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>827</fpage>
            <pub-id pub-id-type="pmid">8144858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartalena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bogazzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tanda</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dell'Unto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bruno-Bossio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bartolomei</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lepri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pinchera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.</article-title>
            <source>N Engl J Med</source>
            <year>1998</year>
            <month>Jan</month>
            <day>08</day>
            <volume>338</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <page-range>73-8</page-range>
            <pub-id pub-id-type="pmid">9420337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonino</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Girelli</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Boscaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fallo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Busnardo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fava</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Life events in the pathogenesis of Graves' disease. A controlled study.</article-title>
            <source>Acta Endocrinol (Copenh)</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>128</volume>
            <issue>4</issue>
            <fpage>293</fpage>
            <page-range>293-6</page-range>
            <pub-id pub-id-type="pmid">8498147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wall</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lahooti</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hibbert</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Champion</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Relationship between Clinical and Immunological Features of Thyroid Autoimmunity and Ophthalmopathy during Pregnancy.</article-title>
            <source>J Thyroid Res</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>698470</fpage>
            <pub-id pub-id-type="pmid">26798548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>RUNDLE</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>WILSON</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy.</article-title>
            <source>Clin Sci</source>
            <year>1945</year>
            <volume>5</volume>
            <issue>3-4</issue>
            <fpage>177</fpage>
            <page-range>177-94</page-range>
            <pub-id pub-id-type="pmid">21011937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ghadiri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Theodoropoulou</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical pathophysiology of thyroid eye disease: The Cone Model.</article-title>
            <source>Eye (Lond)</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>244</fpage>
            <page-range>244-253</page-range>
            <pub-id pub-id-type="pmid">30659242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Normal range of exophthalmos values on orbit computerized tomography in Koreans.</article-title>
            <source>Ophthalmologica</source>
            <year>2001</year>
            <season>May-Jun</season>
            <volume>215</volume>
            <issue>3</issue>
            <fpage>156</fpage>
            <page-range>156-62</page-range>
            <pub-id pub-id-type="pmid">11340383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burch</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Wartofsky</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Graves' ophthalmopathy: current concepts regarding pathogenesis and management.</article-title>
            <source>Endocr Rev</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>747</fpage>
            <page-range>747-93</page-range>
            <pub-id pub-id-type="pmid">8119236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LEBENSOHN</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>THE EYE SIGNS OF GRAVES' DISEASE.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1964</year>
            <month>Apr</month>
            <volume>57</volume>
            <fpage>680</fpage>
            <page-range>680-1</page-range>
            <pub-id pub-id-type="pmid">14139314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naik</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Vasanthapuram</surname>
                <given-names>VH</given-names>
              </name>
            </person-group>
            <article-title>Demographic and clinical profile of 1000 patients with thyroid eye disease presenting to a Tertiary Eye Care Institute in India.</article-title>
            <source>Int Ophthalmol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>231</fpage>
            <page-range>231-236</page-range>
            <pub-id pub-id-type="pmid">32844239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilbard</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Farris</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Ocular surface drying and tear film osmolarity in thyroid eye disease.</article-title>
            <source>Acta Ophthalmol (Copenh)</source>
            <year>1983</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>108</fpage>
            <page-range>108-16</page-range>
            <pub-id pub-id-type="pmid">6687972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chng</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Seah</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Ethnic differences in the clinical presentation of Graves' ophthalmopathy.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>249</fpage>
            <page-range>249-58</page-range>
            <pub-id pub-id-type="pmid">22632362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>NAFFZIGER</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Progressive exophthalmos.</article-title>
            <source>Ann R Coll Surg Engl</source>
            <year>1954</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-24</page-range>
            <pub-id pub-id-type="pmid">13189321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Detorakis</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous medial orbital decompression associated with medial wall remodeling in Graves' orbitopathy.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2014</year>
            <season>Jan-Feb</season>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-80</page-range>
            <pub-id pub-id-type="pmid">24398502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagy</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaldi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Damjanovich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mezosi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lenkey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Szabo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karanyi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Leovey</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Graves' ophthalmopathy: eye muscle involvement in patients with diplopia.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>142</volume>
            <issue>6</issue>
            <fpage>591</fpage>
            <page-range>591-7</page-range>
            <pub-id pub-id-type="pmid">10832104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trokel</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Acaroglu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Reversal of dysthyroid optic neuropathy following orbital fat decompression.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>84</volume>
            <issue>6</issue>
            <fpage>600</fpage>
            <page-range>600-5</page-range>
            <pub-id pub-id-type="pmid">10837384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez-L&#x000f3;pez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sales-Sanz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rebolleda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Casas-Llera</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Gordaliza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jarr&#x000ed;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz-Negrete</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Retrobulbar ocular blood flow changes after orbital decompression in Graves' ophthalmopathy measured by color Doppler imaging.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2011</year>
            <month>Jul</month>
            <day>29</day>
            <volume>52</volume>
            <issue>8</issue>
            <fpage>5612</fpage>
            <page-range>5612-7</page-range>
            <pub-id pub-id-type="pmid">21498614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Werner</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Classification of the eye changes of Graves' disease.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1969</year>
            <month>Oct</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>646</fpage>
            <page-range>646-8</page-range>
            <pub-id pub-id-type="pmid">5394450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Werner</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Modification of the classification of the eye changes of Graves' disease.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1977</year>
            <month>May</month>
            <volume>83</volume>
            <issue>5</issue>
            <fpage>725</fpage>
            <page-range>725-7</page-range>
            <pub-id pub-id-type="pmid">577380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Dyk</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Orbital Graves' disease. A modification of the "NO SPECS" classification.</article-title>
            <source>Ophthalmology</source>
            <year>1981</year>
            <month>Jun</month>
            <volume>88</volume>
            <issue>6</issue>
            <fpage>479</fpage>
            <page-range>479-83</page-range>
            <pub-id pub-id-type="pmid">6894971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mourits</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Prummel</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Wiersinga</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Koornneef</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>1997</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-14</page-range>
            <pub-id pub-id-type="pmid">9302365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polito</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leccisotti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>MRI in Graves orbitopathy: recognition of enlarged muscles and prediction of steroid response.</article-title>
            <source>Ophthalmologica</source>
            <year>1995</year>
            <volume>209</volume>
            <issue>4</issue>
            <fpage>182</fpage>
            <page-range>182-6</page-range>
            <pub-id pub-id-type="pmid">8545089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrett</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Glatt</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Burde</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Gado</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Optic nerve dysfunction in thyroid eye disease: CT.</article-title>
            <source>Radiology</source>
            <year>1988</year>
            <month>May</month>
            <volume>167</volume>
            <issue>2</issue>
            <fpage>503</fpage>
            <page-range>503-7</page-range>
            <pub-id pub-id-type="pmid">3357962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monteiro</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Moura</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Gebrim</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic ability of Barrett's index to detect dysthyroid optic neuropathy using multidetector computed tomography.</article-title>
            <source>Clinics (Sao Paulo)</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <page-range>301-6</page-range>
            <pub-id pub-id-type="pmid">18568237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bartley</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Garrity</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bergstralh</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Gorman</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Comparability of proptosis measurements by different techniques.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>133</volume>
            <issue>6</issue>
            <fpage>813</fpage>
            <page-range>813-8</page-range>
            <pub-id pub-id-type="pmid">12036674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nugent</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Belkin</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Neigel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rootman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Spinelli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graeb</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Graves orbitopathy: correlation of CT and clinical findings.</article-title>
            <source>Radiology</source>
            <year>1990</year>
            <month>Dec</month>
            <volume>177</volume>
            <issue>3</issue>
            <fpage>675</fpage>
            <page-range>675-82</page-range>
            <pub-id pub-id-type="pmid">2243967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiong</surname>
                <given-names>TYV</given-names>
              </name>
              <name>
                <surname>Sundar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Makmur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>HRC</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>YLJ</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>A Novel Method of CT Exophthalmometry in Patients With Thyroid Eye Disease.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2020</year>
            <season>Jan-Feb</season>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-43</page-range>
            <pub-id pub-id-type="pmid">31990744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Imaging in thyroid-associated orbitopathy.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>145</volume>
            <issue>2</issue>
            <fpage>107</fpage>
            <page-range>107-18</page-range>
            <pub-id pub-id-type="pmid">11454505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r46">
          <label>46</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shah</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Khanam</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Orbital Color Doppler Imaging</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">34283486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartalena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tanda</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Manetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dell'Unto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bartolomei</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pinchera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cigarette smoking and treatment outcomes in Graves ophthalmopathy.</article-title>
            <source>Ann Intern Med</source>
            <year>1998</year>
            <month>Oct</month>
            <day>15</day>
            <volume>129</volume>
            <issue>8</issue>
            <fpage>632</fpage>
            <page-range>632-5</page-range>
            <pub-id pub-id-type="pmid">9786811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karlsson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Westermark</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dahlberg</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Jansson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Enoksson</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Ophthalmopathy and thyroid stimulation.</article-title>
            <source>Lancet</source>
            <year>1989</year>
            <month>Sep</month>
            <day>16</day>
            <volume>2</volume>
            <issue>8664</issue>
            <fpage>691</fpage>
            <pub-id pub-id-type="pmid">2570950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prummel</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Wiersinga</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Mourits</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Koornneef</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berghout</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Gaag</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.</article-title>
            <source>Arch Intern Med</source>
            <year>1990</year>
            <month>May</month>
            <volume>150</volume>
            <issue>5</issue>
            <fpage>1098</fpage>
            <page-range>1098-101</page-range>
            <pub-id pub-id-type="pmid">1691908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Krassas</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Bartalena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altea</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boboridis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sivelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>von Arx</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mourits</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Baldeschi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bencivelli</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wiersinga</surname>
                <given-names>W</given-names>
              </name>
              <collab>European Group on Graves' Orbitopathy</collab>
            </person-group>
            <article-title>Selenium and the course of mild Graves' orbitopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>May</month>
            <day>19</day>
            <volume>364</volume>
            <issue>20</issue>
            <fpage>1920</fpage>
            <page-range>1920-31</page-range>
            <pub-id pub-id-type="pmid">21591944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartalena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krassas</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Wiersinga</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Salvi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daumerie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bournaud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sassi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Veronesi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Azzolini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boboridis</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Mourits</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Soeters</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Baldeschi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curr&#x000f2;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>von Arx</surname>
                <given-names>G</given-names>
              </name>
              <collab>European Group on Graves' Orbitopathy</collab>
            </person-group>
            <article-title>Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>97</volume>
            <issue>12</issue>
            <fpage>4454</fpage>
            <page-range>4454-63</page-range>
            <pub-id pub-id-type="pmid">23038682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sisti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Menconi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Profilo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mautone</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mazzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rocchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Latrofa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marin&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>661</fpage>
            <page-range>661-8</page-range>
            <pub-id pub-id-type="pmid">25596664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivera-Grana</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Suhler</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease.</article-title>
            <source>J Clin Exp Ophthalmol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">26807304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajendram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Potts</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Olver</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bremner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hurel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gattamaneni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plowman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bunce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hollinghurst</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Kingston</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Rumsey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>OC</given-names>
              </name>
              <name>
                <surname>Dayan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Uddin</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Protocol for the combined immunosuppression &#x00026; radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial.</article-title>
            <source>Trials</source>
            <year>2008</year>
            <month>Jan</month>
            <day>31</day>
            <volume>9</volume>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">18237441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ye</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>86</volume>
            <issue>2</issue>
            <fpage>247</fpage>
            <page-range>247-255</page-range>
            <pub-id pub-id-type="pmid">27484048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vannucchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Curr&#x000f2;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Campi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Covelli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dazzi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Simonetta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guastella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pignataro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Avignone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beck-Peccoz</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>100</volume>
            <issue>2</issue>
            <fpage>422</fpage>
            <page-range>422-31</page-range>
            <pub-id pub-id-type="pmid">25494967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Ezra</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dailey</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Antonelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gigantelli</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Couch</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Shriver</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Hink</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Magni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Teprotumumab for Thyroid-Associated Ophthalmopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>04</day>
            <volume>376</volume>
            <issue>18</issue>
            <fpage>1748</fpage>
            <page-range>1748-1761</page-range>
            <pub-id pub-id-type="pmid">28467880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ponto</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>320</fpage>
            <page-range>320-32</page-range>
            <pub-id pub-id-type="pmid">21239515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyons</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Rootman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Orbital decompression for disfiguring exophthalmos in thyroid orbitopathy.</article-title>
            <source>Ophthalmology</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>101</volume>
            <issue>2</issue>
            <fpage>223</fpage>
            <page-range>223-30</page-range>
            <pub-id pub-id-type="pmid">8115142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Elner</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of lateral and medial orbital decompression for the treatment of compressive optic neuropathy in thyroid eye disease.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2011</year>
            <season>Jan-Feb</season>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-11</page-range>
            <pub-id pub-id-type="pmid">20736873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sellari-Franceschini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lenzi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muscatello</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rocchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Altea</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Megna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Lateral wall orbital decompression in Graves' orbitopathy.</article-title>
            <source>Int J Oral Maxillofac Surg</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-20</page-range>
            <pub-id pub-id-type="pmid">19914801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben Simon</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Schwarcz</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>McCann</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Strabismus after deep lateral wall orbital decompression in thyroid-related orbitopathy patients using automated hess screen.</article-title>
            <source>Ophthalmology</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>113</volume>
            <issue>6</issue>
            <fpage>1050</fpage>
            <page-range>1050-5</page-range>
            <pub-id pub-id-type="pmid">16751042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kennedy</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Goodstein</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Zinreich</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic transnasal orbital decompression.</article-title>
            <source>Arch Otolaryngol Head Neck Surg</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>116</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-82</page-range>
            <pub-id pub-id-type="pmid">2306344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Konuk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hasanreiso&#x0011f;lu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Balanced orbital decompression combined with fat removal in Graves ophthalmopathy: do we really need to remove the third wall?</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>112</fpage>
            <page-range>112-8</page-range>
            <pub-id pub-id-type="pmid">12644756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>OGURA</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>WALSH</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>The transantral orbital decompression operation for progressive exophthalmos.</article-title>
            <source>Laryngoscope</source>
            <year>1962</year>
            <month>Aug</month>
            <volume>72</volume>
            <fpage>1078</fpage>
            <page-range>1078-97</page-range>
            <pub-id pub-id-type="pmid">14481327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kennerdell</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Maroon</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>An orbital decompression for severe dysthyroid exophthalmos.</article-title>
            <source>Ophthalmology</source>
            <year>1982</year>
            <month>May</month>
            <volume>89</volume>
            <issue>5</issue>
            <fpage>467</fpage>
            <page-range>467-72</page-range>
            <pub-id pub-id-type="pmid">6896562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olivari</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Transpalpebral decompression of endocrine ophthalmopathy (Graves' disease) by removal of intraorbital fat: experience with 147 operations over 5 years.</article-title>
            <source>Plast Reconstr Surg</source>
            <year>1991</year>
            <month>Apr</month>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>627</fpage>
            <page-range>627-41; discussion 642-3</page-range>
            <pub-id pub-id-type="pmid">2008461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leone</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Piest</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Medial and lateral wall decompression for thyroid ophthalmopathy.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1989</year>
            <month>Aug</month>
            <day>15</day>
            <volume>108</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-6</page-range>
            <pub-id pub-id-type="pmid">2757096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hortaleza</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Strabismus after balanced medial plus lateral wall versus lateral wall only orbital decompression for dysthyroid orbitopathy.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>271</fpage>
            <page-range>271-7</page-range>
            <pub-id pub-id-type="pmid">10923974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rootman</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Orbital decompression for thyroid eye disease.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-104</page-range>
            <pub-id pub-id-type="pmid">28343872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ye&#x0015f;ilta&#x0015f;</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nd&#x000fc;z</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic Orbital Inflammation: Review of Literature and New Advances.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2018</year>
            <season>Apr-Jun</season>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>71</fpage>
            <page-range>71-80</page-range>
            <pub-id pub-id-type="pmid">30122852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olsen</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Orbital lymphoma.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-66</page-range>
            <pub-id pub-id-type="pmid">30144455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r73">
          <label>73</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Koenen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Waseem</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Orbital Floor Fracture</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30521246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banerjee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alam</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kundu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Poonam</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Orbital and adnexal amyloidosis: Thirty years experience at a tertiary eye care center.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2021</year>
            <month>May</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>1161</fpage>
            <page-range>1161-1166</page-range>
            <pub-id pub-id-type="pmid">33913851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142674.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>A review of surgical techniques to correct upper eyelid retraction associated with thyroid eye disease.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>391</fpage>
            <page-range>391-3</page-range>
            <pub-id pub-id-type="pmid">21730842</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
